NIH P01 Grants — Program Project Grant

Recent P01 awards from NIH RePORTER

Examples of funded P01 projects across the last two fiscal years. The matching-award count comes from the full result set; funding totals, averages, rankings, and examples use the first 500 records returned by NIH RePORTER. Figures reflect a snapshot last refreshed on September 5, 2026.

Example P01 projects from the sample

• Harnessing a Two-State FEP LHS to Optimize Engagement and Prevent Disengagement in CSC

  5P01MH139228-03
  MELANIE BENNETT · UNIVERSITY OF MARYLAND BALTIMORE, MD · $1,530,536 · awarded Aug 27, 2026 · NIH

  Overall Component - Abstract This Program Project Grant entitled Harnessing a Two-State FEP LHS to Optimize Engagement and Prevent Disengagement in CSC will leverage Connection Learning Healthcare System (CLHS) - a two-state learning healthcare system and Early Psychosis Intervention Network (EPINET) hub (MH120550, Bennett PI) - to pursue integrated…

• Multi-disciplinary Approaches to HDL Structure, Assembly, and Functional Heterogeneity

  5P01HL128203-09
  W Davidson · UNIVERSITY OF CINCINNATI, OH · $2,487,019 · awarded Aug 27, 2026 · NIH

  SUMMARY (Entire PPG) The development of new cardioprotective drugs and accurate metrics for cardiovascular risk is being hindered, we believe, by the failure to correctly identify the cardioprotective forms of high-density lipoprotein (HDL) and inadequate knowledge about the mechanisms that remove cholesterol from the artery wall. This renewal application…

• Redefining Chiari Type I Malformation and its Impact on Brain Development

  5P01NS131131-04
  Chenyang Lu · WASHINGTON UNIVERSITY, MO · $1,485,292 · awarded Aug 27, 2026 · NIH

  PROJECT SUMMARY Overall: Abstract Since its original description by Hans Chiari in the 1890s, Chiari type I malformation (CM) has been defined as caudal displacement (ectopia) of the cerebellar tonsils below the foramen magnum. This definition oversimplifies the complex range of craniovertebral junction pathology affecting more than 1% of the population and…

• Mechanisms of Early Breast Cancer Local and Distant Relapse

  1P01CA295557-01A1
  Julio Aguirre-Ghiso · ALBERT EINSTEIN COLLEGE OF MEDICINE, NY · $2,038,280 · awarded Aug 26, 2026 · NIH

  Local and metastatic relapse is responsible for the majority of cancer related morbidity and deaths. Relapse can occur after long periods of dormancy despite the use of adjuvant therapies. However, lack of knowledge on the specific biology of disseminated dormant residual disease prevents it from being targeted specifically. The early lesions of breast…

• The intersection of immunity and cardiovascular diseases

  5P01HL174442-02
  David Harrison · VANDERBILT UNIVERSITY MEDICAL CENTER, TN · $2,874,543 · awarded Aug 26, 2026 · NIH

  PROJECT SUMMARY The overall goal of the Intersection of Immunity and Cardiovascular Disease (IICD) Program Project Grant is to understand how immune cells are activated and contribute to target organ damage in hypertension and autoimmune diseases. Our overarching hypothesis is that activated immune cells promote renal and vascular dysfunction and damage,…

• Adult Leukemia Research Center

  5P01CA018029-50
  Geoffrey HILL · FRED HUTCHINSON CANCER CENTER, WA · $4,395,431 · awarded Aug 25, 2026 · NIH

  Project Summary/Abstract Overall Acute Myeloid Leukemia (AML) and multiple myeloma (MM) are diseases of the elderly, with median incidence of disease beyond 60 years of age. The mainstay of curative therapy for adult acute leukemia over the last two decades in younger patients has been allogeneic stem cell or bone marrow transplantation (hereafter referred…

• Leveraging complex observational data to understand human influenza transmission

  1P01AI202602-01
  Adam Lauring · UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI · $2,959,454 · awarded Aug 25, 2026 · NIH

  Project Summary – Overall Despite major advancements in the prevention of severe influenza infection through vaccination, treatment, and air quality, influenza still accounts for substantial morbidity and mortality worldwide and in the United States. While animal models and experimental systems allow for precise control and isolation of specific factors…

• Mutant p53 in Tumorigenesis, Invasion, and Metastasis

  5P01CA291694-02
  James Manfredi · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY · $2,612,137 · awarded Aug 25, 2026 · NIH

  PROGRAM SUMMARY The p53 protein has been extensively studied for its tumor suppressor activity in human cancer. Missense mutation of the TP53 gene is a common event in tumors. This contrasts with other tumor suppressors where deletion or loss of expression is more prevalent. Studies in genetically engineered mice have shown that knock- in of particular…

• Cardiac Neuromodulation: Mechanisms and Therapeutics

  5P01HL164311-04
  KALYANAM SHIVKUMAR · UNIVERSITY OF CALIFORNIA LOS ANGELES, CA · $2,256,541 · awarded Aug 25, 2026 · NIH

  PROJECT SUMMARY/ABSTRACT - Overall Our Program Project Grant (PPG) focuses on the complex interplay between the chronically infarcted heart and sympathetic nervous system (SNS), with the goal of defining precise mechanisms of ventricular arrhythmias and sudden cardiac death. The overarching objective of the PPG is to test ‘The Spatiotemporal Heterogeneity…

• Novel cell and gene therapy for HIV cure

  5P01AI191224-02
  J. Victor Garcia-Martinez · UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL · $2,817,259 · awarded Aug 24, 2026 · NIH

  Modified Project Summary/Abstract Section This application represents a well-integrated multi-project research program to improve and implement an emerging gene and cell therapy technology for HIV cure. Previous work demonstrated that a rhesus CMV based SIV vaccine protected 50% of macaques from persistent SIV infection with the correlate of protection…

• A Prospective Study of Persistent Symptoms of Lyme Disease

  3P01AI181934-03S1
  Linden Hu · TUFTS UNIVERSITY BOSTON, MA · $2,143,584 · awarded Aug 21, 2026 · NIH

  ABSTRACT: OVERALL Despite years of research, there is no diagnostic test for post-treatment Lyme disease syndrome (PTLDS); there is no consensus treatment for PTLDS; there is no agreement on the mechanisms causing disease or even how frequently it happens. And while there have been intriguing findings by many outstanding researchers, they have not been…

• Molecular Pathogenesis of the Hamartoma Syndromes

  5P01CA120964-19
  David Kwiatkowski · BRIGHAM AND WOMEN'S HOSPITAL, MA · $2,054,545 · awarded Aug 21, 2026 · NIH

  Overall - Project Summary/Abstract The hamartoma syndromes include those due to mutations in TSC1 or TSC2, PTEN, and LKB1. These genes function in classic tumor suppressor gene fashion to cause easily recognized and unique clinical syndromes; each of these genes is also involved in the development of typical adult malignancies. In addition, a variety of…

Compare nearby NIH grant mechanisms

Searchers often land on P01 while deciding between adjacent NIH activity codes. Compare scope, NIH staff involvement, budget scale, and applicant stage before choosing a funding opportunity.